Stroke, Vol 20, 1553-1556, Copyright © 1989 by American Heart Association
T Mima, M Yanagisawa, T Shigeno, A Saito, K Goto, K Takakura and T Masaki
We investigated the in vivo vasoconstrictor effect of endothelin, a
recently characterized vasoconstrictor peptide from vascular endothelium,
in the basilar arteries of five cats and five dogs. Basilar artery caliber
was angiographically measured under anesthesia before (control) and after
either vertebral artery infusion or cisternal injection of the peptide. In
cats, 5-500 pmol endothelin induced a dose-dependent basilar artery
contraction in vivo when injected intracisternally; within 3 minutes after
injection of 500 pmol endothelin, basilar artery caliber was decreased by
73 +/- 4% compared with control diameter before injection. The
vasoconstriction was extremely long-lasting; no significant recovery of
basilar artery caliber was observed for up to 2 hours after injection. In
contrast, infusion of up to 3,000 pmol endothelin into the vertebral artery
had no appreciable effect on basilar artery caliber. Similar results were
obtained in dogs; vasoconstriction was maintained for as long as 12 hours.
Our observations suggest that endothelin acts in cerebral vessels from the
adventitial side, not from the luminal side, possibly due to the presence
of the blood-arterial wall barrier. The long- lasting nature of
endothelin-induced constriction of the cerebral arteries in vivo suggests
that the peptide might be involved in the pathogenesis of cerebral
vasospasm.
ARTICLES
Endothelin acts in feline and canine cerebral arteries from the adventitial side
Department of Neurosurgery, University of Tokyo, Japan.
This article has been cited by other articles:
![]() |
C.-L. Lin, A. S. Dumont, S.-C. Wu, C.-J. Wang, S.-L. Howng, Y.-F. Huang, W.-Y. Wong, N. F. Kassell, A. Y. Jeng, and A.-L. Kwan 17{beta}-Estradiol Inhibits Endothelin-1 Production and Attenuates Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage. Experimental Biology and Medicine, June 1, 2006; 231(6): 1054 - 1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sonveaux, C. Dessy, P. Martinive, X. Havaux, B. F. Jordan, B. Gallez, V. Gregoire, J.-L. Balligand, and O. Feron Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment Cancer Res., May 1, 2004; 64(9): 3209 - 3214. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fa{beta}bender, B. Hodapp, S. Rossol, T. Bertsch, J. Schmeck, S. Schutt, M. Fritzinger, P. Horn, P. Vajkoczy, M. Wendel-Wellner, et al. Endothelin-1 in Subarachnoid Hemorrhage : An Acute-Phase Reactant Produced by Cerebrospinal Fluid Leukocytes Stroke, December 1, 2000; 31(12): 2971 - 2975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shihara, Y. Hirooka, N. Hori, I. Matsuo, T. Tagawa, S. Suzuki, N. Akaike, and A. Takeshita Endothelin-1 increases the neuronal activity and augments the responses to glutamate in the NTS Am J Physiol Regulatory Integrative Comp Physiol, August 1, 1998; 275(2): R658 - R665. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roux, V. Breu, T. Giller, W. Neidhart, H. Ramuz, P. Coassolo, J. P. Clozel, and M. Clozel Ro 61-1790, a New Hydrosoluble Endothelin Antagonist: General Pharmacology and Effects on Experimental Cerebral Vasospasm J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1110 - 1118. [Abstract] [Full Text] |
||||
![]() |
Y. Lampl, G. Fleminger, R. Gilad, R. Galron, I. Sarova-Pinhas, and M. Sokolovsky Endothelin in Cerebrospinal Fluid and Plasma of Patients in the Early Stage of Ischemic Stroke Stroke, October 1, 1997; 28(10): 1951 - 1955. [Abstract] [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |